col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


44 Ergebisse       Seite 1

 [1] 
Elsevier: Bioorganic & Medicinal Chemistry Letters
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2025―Apr―17 Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment Peisen Zheng, Guanguan Li, Yuanguang Chen, Shuo Li, Sidi Yang, Deyin Guo, et al. (+2)
2 [GO] 2025―Mrz―27 Discovery of 4-((quinolin-8-ylthio)methyl)benzamide derivatives as a new class of SARS-CoV-2 nsp13 inhibitors Danchen Fan, Yuanting Huang, Rui Yao, Guo Zhang, Shengyong Yang, Linli Li
3 [GO] 2025―Mrz―11 Research progress on critical viral protease inhibitors for coronaviruses and enteroviruses Shulei Hu, Qiuyu Zhong, Xiong Xie, Shurui Zhang, Jinlin Wang, Hong Liu, Wenhao Dai
4 [GO] 2025―Mrz―06 Discovery of Flavonol derivatives as porcine reproductive and respiratory syndrome virus inhibitors Zhi-Zheng Wang, Chen-Xu Xiao, Wen-Li Huang, Yang Hu, Hui-Ting Zhang, Zhang Liu, et al. (+2)
5 [GO] 2024―Nov―21 Synthesis and Structure-Activity relationship of covalent inhibitors of SARS-CoV-2 papain-like protease with antiviral potency Catherine C. Rouch, Arnab K. Chatterjee, Connor McCarty, Lirui Song, Alan Chu, Kristen Johnson, et al. (+8)
6 [GO] 2024―Nov―01 Synthesis and evaluation of N-arylindazole-3-carboxamide derivatives as novel antiviral agents against SARS-CoV-2 Jun Young Lee, Sangeun Jeon, Jung-Eun Cho, Sungmin Kim, Hyoung Rae Kim, Hyeung-geun Park, et al. (+2)
7 [GO] 2024―Nov―01 Structural basis of the C-terminal domain of SARS-CoV-2 N protein in complex with GMP reveals critical residues for RNA interaction Xincheng Ni, Yinze Han, Jiao Yu, Renjie Zhou, Jian Lei
8 [GO] 2024―Okt―31 Design, synthesis, and biological evaluation of dithiocarbamate derivatives as SARS-CoV-2 Mpro inhibitors Jin-Qi Peng, Ya-Qi Xiao, Jiao Long, Shuang-Shuang Zhang, Yuan-Yuan Zhu, Shuang-Xi Gu
9 [GO] 2024―Sep―07 Assessing the inhibitory effects of some secondary amines, thioureas and 1,3-dimethyluracil conjugates of (-)-cytisine and thermopsine on the RNA-dependent RNA polymerase of SARS-CoV-1 and SARS-CoV-2 Yeh Chen, Mann-Jen Hour, Chen-Sheng Lin, Young-Sheng Chang, Zan-Yu Chen, Alena V. Koval’skaya, et al. (+3)
10 [GO] 2024―Aug―30 Discovery of the potent covalent inhibitor with an acrylate warhead for SARS-CoV-2 3CL protease Wen Shen, Xinyao Chen, Liping Zhou, Yan Cheng, Yan Zhang, Xiangrui Jiang, et al. (+2)
11 [GO] 2024―Aug―16 Inhibitors of Rickettsia prowazekii methionine aminopeptidase 1 identified from the Pandemic Response Box Ishpriya Sharma, Drashti Daraji, James R. Horn, Timothy J. Hagen
12 [GO] 2024―Jun―25 Machine learning-based QSAR and LB-PaCS-MD guided design of SARS-CoV-2 main protease inhibitors Borwornlak Toopradab, Wanting Xie, Lian Duan, Kowit Hengphasatporn, Ryuhei Harada, Silpsiri Sinsulpsiri, et al. (+4)
13 [GO] 2024―Mrz―19 An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting Mpro Jing Zhang, Lili Zhao, Yuxin Bai, Shanshan Li, Meifang Zhang, Bo Wei, et al. (+6)
14 [GO] 2024―Feb―27 Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives Blake M. Shellenberger, Olivia N. Basile, Joel Cassel, Morgan R. Olsen, Joseph M. Salvino, Luis J. Montaner, et al. (+2)
15 [GO] 2024―Feb―21 Discovery of an ellipticine derivative as TLR3 inhibitor against influenza A virus and SARS-CoV-2 Yue Pan, Qiuyue Fu, Yinyan Li, Jie Yang, Kui Cheng
16 [GO] 2024―Feb―02 Exploring 2-methyl-substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2 Ryohto Koharazawa, Mayu Hayakawa, Kazuki Takeda, Kotone Miyazaki, Chisato Tode, Yoshihisa Hirota, Yoshitomo Suhara
17 [GO] 2023―Nov―24 Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies Jichun Li, Qing Li, Shuai Xia, Jiahuang Tu, Longbo Zheng, Qian Wang, et al. (+2)
18 [GO] 2023―Nov―08 Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation Xiaodong Dou, Qi Sun, Yameng Liu, Yangbin Lu, Caifang Zhang, Guofeng Xu, et al. (+7)
19 [GO] 2023―Okt―20 Pyrazolidinone-Based Peptidomimetic SARS-CoV-2 Mpro inhibitors Daniels Jelisejevs, Anna Lina Bula, Linda Kinena
20 [GO] 2023―Sep―27 SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads Arun K. Ghosh, Dana Shahabi, Mackenzie E.C. Imhoff, Satish Kovela, Ashish Sharma, Shin-ichiro Hattori, et al. (+3)
21 [GO] 2023―Jul―11 Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease Falu Wang, Rui Zeng, Jingxin Qiao, Anjie Xia, Yueshan Li, Feng Li, et al. (+5)
22 [GO] 2023―Mai―12 Discovery of Novel Bicyclic[3.3.0]proline Peptidyl α-Ketoamides as Potent 3CL-Protease Inhibitors for SARS-CoV-2 Xiaoxin Chen, Peng Li, Jianzhou Huang, Yaxun Yang, Haoyu Zhang, Zheng Wang, et al. (+7)
23 [GO] 2023―Mrz―15 Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors Nihong Guo, Chong Huang, Jinxin Qiao, Yueyue Li, Yifei Wang, Anjie Xia, et al. (+4)
24 [GO] 2023―Mrz―02 Discovery of 2-Aminoquinolone Acid Derivatives as Potent Inhibitors of SARS-CoV-2 Young Sup Shin, Jun Young Lee, Sangeun Jeon, Subeen Myung, Hyun June Gong, Seungtaek Kim, et al. (+3)
25 [GO] 2023―Mrz―01 Hydroxy-xanthones as promising antiviral agents: Synthesis and biological evaluation against human coronavirus OC43 Bethanie Dean, Gemma Cooper, Maitreyi Shivkumar, Timothy J. Snape
26 [GO] 2023―Feb―08 Synthesis and biological evaluation of new β-D-N4-hydroxycytidine analogs against SARS-CoV-2, influenza viruses and DENV-2 Yeon Jin An, Se Myeong Choi, Eun Rang Choi, Ye Eun Nam, Eun Woo Seo, Soo Bin Ahn, et al. (+3)
27 [GO] 2022―Dez―29 Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease Daiki Katagishi, Daisuke Yasuda, Kyoko Takahashi, Shigeo Nakamura, Tadahiko Mashino, Tomoyuki Ohe
28 [GO] 2022―Sep―14 COVID-19: Vaccines and therapeutics Swapna Ponnampalli, Naga Venkata Suryanarayana Birudukota, Ahmed Kamal
29 [GO] 2022―Jun―24 Discovery of 2-Thiobenzimidazoles as Noncovalent Inhibitors of SARS-CoV-2 Main Protease Davide Deodato, Nadeem Asad, Timothy M. Dore
30 [GO] 2022―Apr―12 Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (Mpro) inhibitors Emily G. Hicks, Sylvie E. Kandel, Jed N. Lampe
31 [GO] 2022―Feb―16 Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir Sven Ullrich, Kasuni B. Ekanayake, Gottfried Otting, Christoph Nitsche
32 [GO] 2022―Jan―05 Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold Weixiong Chen, Bo Feng, Sheng Han, Peipei Wang, Wuhong Chen, Yi Zang, et al. (+2)
33 [GO] 2021―Aug―19 Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors Sven Ullrich, Vishnu M. Sasi, Mithun C. Mahawaththa, Kasuni B. Ekanayake, Richard Morewood, Josemon George, et al. (+6)
34 [GO] 2021―Jul―14 A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors Subramanyam Vankadara, Yun Xuan Wong, Boping Liu, Yi Yang See, Li Hong Tan, Qian Wen Tan, et al. (+7)
35 [GO] 2021―Mai―03 Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library Joo-Youn Lee, Chih-Jung Kuo, Jin Soo Shin, Eunhye Jung, Po-Huang Liang, Young-Sik Jung
36 [GO] 2021―Mai―01 Exploring the potential of novel phenolic compounds as potential therapeutic candidates against SARS-CoV-2, using quantum chemistry, molecular docking and dynamic studies Maimoona Zia, Shabbir Muhammad, Shamsa Bibi, Sumra Wajid Abbasi, Abdullah G. Al-Sehemi, Aijaz Rasool Chaudhary, Fu Quan Bai
37 [GO] 2021―Apr―20 Development of ciclesonide analogues that block SARS-CoV-2 RNA replication Genichiro Tsuji, Kenzo Yonemitsu, Takahito Ito, Yuta Yanase, Masashi Uema, Nobumichi Ohoka, et al. (+3)
38 [GO] 2021―Mrz―26 Identification of Non-Covalent SARS-CoV-2 Main Protease Inhibitors by a Virtual Screen of Commercially Available Drug-Like Compounds Linlin Zhang, McClane Howland, Rolf Hilgenfeld, Marc O. Anderson, Scott Eagon
39 [GO] 2021―Mrz―20 SARS-CoV-2 main protease inhibition by compounds isolated from Luffa cylindrica using molecular docking Thao Quyen Cao, Jeong Ah Kim, Mi Hee Woo, Byung Sun Min
40 [GO] 2021―Mrz―07 Application of Niclosamide and Analogs as Small Molecule Inhibitors of Zika Virus and SARS-Cov-2 Infection Khalida Shamim, Miao Xu, Xin Hu, Emily M Lee, Xiao Lu, Ruili Huang, et al. (+18)
41 [GO] 2021―Mrz―02 Design, Synthesis and Biological Evaluation of 2-Aminoquinazolin-4(3H)-one Derivatives as Potential SARS-CoV-2 and MERS-CoV Treatments Jun Young Lee, Young Sup Shin, Sangeun Jeon, Se In Lee, Soojin Noh, Jung-Eun Cho, et al. (+5)
42 [GO] 2020―Nov―05 Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2 Young Sup Shin, Jun Young Lee, Soojin Noh, Yoonna Kwak, Sangeun Jeon, Sunoh Kwon, et al. (+6)
43 [GO] 2020―Aug―08 Identification of 4-Anilino-6-aminoquinazoline Derivatives as Potential MERS-CoV Inhibitors Jun Young Lee, Young Sup Shin, Jihye Lee, Sunoh Kwon, Young-hee Jin, Min Seong Jang, et al. (+4)
44 [GO] 2020―Jul―02 The SARS-CoV-2 main protease as drug target Sven Ullrich, Christoph Nitsche
 [1] 

44 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.003 sec